De novo natural anti-M alloantibody emergence in severe Coronavirus Disease 2019.


Journal

Journal of infection and public health
ISSN: 1876-035X
Titre abrégé: J Infect Public Health
Pays: England
ID NLM: 101487384

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 26 01 2022
revised: 25 10 2022
accepted: 27 10 2022
pubmed: 21 11 2022
medline: 7 12 2022
entrez: 20 11 2022
Statut: ppublish

Résumé

The immune response is a key player in the course of SARS-CoV-2 infection, and is often seriously dysfunctional in severe Coronavirus Disease 2019. The hyperinflammatory status has been described to be accompanied by the appearance of autoantibodies. In a lethal COVID-19 infection, we observed the emergence of a de novo natural alloantibody which targeted the M antigen from the MNS blood group on red blood cells (RBC) without evidence of any cross-reaction with SARS-CoV-2 antigens. This IgM lambda alloantibody was unmutated and unswitched. Here, we describe for the first time the emergence of a bystander de novo natural alloantibody against RBCs in a severe COVID-19 patient, highlighting the extra-follicular humoral response reported in these cases.

Identifiants

pubmed: 36403401
pii: S1876-0341(22)00290-8
doi: 10.1016/j.jiph.2022.10.025
pmc: PMC9628129
pii:
doi:

Substances chimiques

Blood Group Antigens 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1455-1458

Informations de copyright

Copyright © 2022. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Conflict of interest Authors have no competing interest to disclose.

Références

Transfusion. 2020 Apr;60(4):831-839
pubmed: 32061102
Cell. 2020 Oct 1;183(1):143-157.e13
pubmed: 32877699
Blood. 2020 Nov 12;136(20):2290-2295
pubmed: 32959052
Nat Immunol. 2020 Dec;21(12):1506-1516
pubmed: 33028979
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Blood. 2020 May 14;135(20):1750-1758
pubmed: 32243509
Blood. 2020 Aug 6;136(6):766-768
pubmed: 32559762
Ann Hematol. 2020 Jul;99(7):1679-1680
pubmed: 32542444
Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7162-7184
pubmed: 34859882
Travel Med Infect Dis. 2021 Jan-Feb;39:101911
pubmed: 33186686
Immunohematology. 2009;25(3):95-101
pubmed: 20406014
EBioMedicine. 2020 May;55:102763
pubmed: 32361250

Auteurs

Robin Jeannet (R)

INSERM CIC 1435, CHU Dupuytren, and UMR CNRS 7276 INSERM 1262, Université de Limoges, Limoges, France. Electronic address: Robin.jeannet@unilim.fr.

Alexandra Descazeaud (A)

Laboratoire d'Immunohématologie, Établissement Français du Sang Nouvelle-Aquitaine, Limoges, France. Electronic address: Alexandra.Descazeaud@efs.sante.fr.

Thomas Daix (T)

INSERM CIC 1435 and Réanimation polyvalente, CHU Dupuytren, and INSERM UMR 1092, Université de Limoges, Limoges, France. Electronic address: thomas.daix@chu-limoges.fr.

Hélène Pauthier (H)

Laboratoire d'Immunohématologie, Établissement Français du Sang Nouvelle-Aquitaine, Limoges, France. Electronic address: Helene.Pauthier@efs.sante.fr.

Virginie Pascal (V)

UMR CNRS 7276, INSERM 1262, Université de Limoges, and Laboratoire d'Immunologie, CHU Dupuytren, Limoges, France. Electronic address: Virginie.PASCAL@chu-limoges.fr.

Sébastien Hantz (S)

UMR INSERM 1092, RESINFIT, Université de Limoges, and Centre National de Référence des Herpèsvirus and Service de Bactériologie, Virologie et Hygiène, CHU Dupuytren, Limoges, France. Electronic address: Sebastien.Hantz@chu-limoges.fr.

Sophie Le Cam (SL)

Laboratoire de qualification biologique des dons, Établissement Français du Sang Centre-Pays de la Loire, Angers, France. Electronic address: sophie.lecam@efs.sante.fr.

Bruno Francois (B)

INSERM CIC 1435 and Réanimation polyvalente, CHU Dupuytren, and INSERM UMR 1092, Université de Limoges, Limoges, France. Electronic address: b.francois@unilim.fr.

Jean Feuillard (J)

UMR CNRS 7276 / INSERM 1262 CRIBL and Laboratoire d'Hématologie, Faculté de Médecine and CHU Dupuytren, Limoges, France. Electronic address: jean.feuillard@unilim.fr.

Xavier Lafarge (X)

INSERM U1035 Biothérapie des Maladies Génétiques, Inflammatoires et Cancers, and Direction Médicale, Établissement Français du Sang Nouvelle-Aquitaine, Bordeaux, France. Electronic address: xavier.lafarge@efs.sante.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH